Table1_MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer.DOCX

MicroRNAs (miRNAs) are key regulators in immune surveillance and immune escape as well as modulators in the metastatic process of breast cancer cells. We evaluated the differential expression of plasma miR-10b, miR-19a, miR-20a, miR-126 and miR-155, which regulate immune response in breast cancer progression and we investigated their clinical relevance in the outcomes of breast cancer patients. Plasma samples were obtained from early (eBC; n = 140) and metastatic (mBC; n = 64) breast cancer patients before adjuvant or first-line chemotherapy, respectively. Plasma miRNA expression levels were assessed by qRT-PCR. We revealed a 4-miRNA panel consisted of miR-19a, miR-20a, miR-126, and miR-155 able to discriminate eBC from mBC patients with an AUC of 0.802 (p st-line chemotherapy can distinguish disease status and emerge as independent predictors for outcomes of breast cancer patients.</p

Additional file 1: of Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer

Table S1. Tenfold cross-validation results of nine different sets of combinations of predictor variables. (DOCX 13 kb

Table2_MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer.docx

MicroRNAs (miRNAs) are key regulators in immune surveillance and immune escape as well as modulators in the metastatic process of breast cancer cells. We evaluated the differential expression of plasma miR-10b, miR-19a, miR-20a, miR-126 and miR-155, which regulate immune response in breast cancer progression and we investigated their clinical relevance in the outcomes of breast cancer patients. Plasma samples were obtained from early (eBC; n = 140) and metastatic (mBC; n = 64) breast cancer patients before adjuvant or first-line chemotherapy, respectively. Plasma miRNA expression levels were assessed by qRT-PCR. We revealed a 4-miRNA panel consisted of miR-19a, miR-20a, miR-126, and miR-155 able to discriminate eBC from mBC patients with an AUC of 0.802 (p st-line chemotherapy can distinguish disease status and emerge as independent predictors for outcomes of breast cancer patients.</p

Presentation1_MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer.PPTX

MicroRNAs (miRNAs) are key regulators in immune surveillance and immune escape as well as modulators in the metastatic process of breast cancer cells. We evaluated the differential expression of plasma miR-10b, miR-19a, miR-20a, miR-126 and miR-155, which regulate immune response in breast cancer progression and we investigated their clinical relevance in the outcomes of breast cancer patients. Plasma samples were obtained from early (eBC; n = 140) and metastatic (mBC; n = 64) breast cancer patients before adjuvant or first-line chemotherapy, respectively. Plasma miRNA expression levels were assessed by qRT-PCR. We revealed a 4-miRNA panel consisted of miR-19a, miR-20a, miR-126, and miR-155 able to discriminate eBC from mBC patients with an AUC of 0.802 (p st-line chemotherapy can distinguish disease status and emerge as independent predictors for outcomes of breast cancer patients.</p

Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide

<div><p>Background</p><p>The aim of the study was to evaluate the predictive value of genes involved in the action of cisplatin-etoposide in Small Cell Lung Cancer (SCLC).</p> <p>Methods</p><p>184 SCLC patients’ primary tumour samples were analyzed for <i>ERCCI, BRCA1, ATP7B, PKM2</i><i>TOPOI, TOPOIIA</i>, <i>TOPOIIB</i> and <i>C-MYC</i> mRNA expression. All patients were treated with cisplatin-etoposide.</p> <p>Results</p><p>The patients’ median age was 63 years and 120 (65%) had extended stage, 75 (41%) had increased LDH serum levels and 131 (71%) an ECOG performance status was 0-1. Patients with limited stage, whose tumours expressed high <i>ERCC1</i> (<i>p</i>=0.028), <i>PKM2</i> (<i>p</i>=0.046), <i>TOPOI</i> (<i>p</i>=0.008), <i>TOPOIIA</i> (<i>p</i>=0.002) and <i>TOPOIIB</i> (p<0.001) mRNA had a shorter Progression Free Survival (PFS). In limited stage patients, high expression of <i>ERCC1</i> (<i>p</i>=0.014), <i>PKM2</i> (<i>p</i>=0.026), <i>TOPOIIA</i> (<i>p</i>=0.021) and <i>TOPOIIB</i> (<i>p</i>=0.019) was correlated with decreased median overall survival (mOS) while in patients with extended stage, only high <i>TOPOIIB</i> expression had a negative impact on Os (<i>p</i>=0.035). The favorable expression signature expression signature (low expression of <i>ERCC1</i>, PKM2, <i>TOPOIIA</i> and <i>TOPOIIB</i>) was correlated with significantly better PFS and Os in both LS-SCLC (<i>p</i><0.001 and <i>p</i>=0.007, respectively) and ES-SCLC (<i>p</i>=0.007 and (<i>p</i>=0.011, respectively) group. The unfavorable expression signature was an independent predictor for poor PFS (HR: 3.18; <i>p</i>=0.002 and HR: 3.14; <i>p</i>=0.021) and Os (HR: 4.35; <i>p=</i>0.001and HR: 3.32; <i>p</i>=0.019) in both limited and extended stage, respectively.</p> <p>Conclusions</p><p>Single gene’s expression analysis as well as the integrated analysis of <i>ERCC1</i>, <i>PKM2, TOPOIIA</i> and <i>TOPOIIB</i> may predict treatment outcome in patients with SCLC. These findings should be further validated in a prospective study.</p> </div

Predictive value of the expression signature (favorable: low <i>ERCC1, PKM2, TOPOIIA</i> and <i>TOPOIIB</i> mRNA levels) in SCLC.

<p>A. Correlation of expression signature with Progression Free Survival in Limited Stage-SCLC. B. Correlation of expression signature with Overall Survival in Limited Stage-SCLC. C. Correlation of expression signature with Progression Free Survival in Extended Stage-SCLC. D. Correlation of expression signature with Overall Survival in Extended Stage-SCLC.</p

Overall Survival in Limited Stage-SCLC.

<p>A. <i>ERCC1</i> mRNA levels and Overall Survival in Limited Stage-SCLC. B. <i>PKM2</i> mRNA levels and Overall Free Survival in Limited Stage-SCLC. C. <i>TOPOIIA</i> mRNA levels and Overall Free Survival in Limited Stage-SCLC. <i>D</i>. <i>TOPOIIB</i> mRNA levels and Overall Free Survival in Limited Stage-SCLC. E. <i>TOPOIIB</i> mRNA levels and Overall Free Survival in Extended Stage-SCLC.</p

Progression Free Survival to salvage treatment with an anti-EGFR monoclonal (stratified for the treatment line) antibody according to <i>BRAF</i>^<i>V600E</i>mutation in 273 patients with metastatic Colorectal Cancer (A) and Median Overall Survival to salvage treatmentwith an anti-EGFR monoclonal antibody (stratified for the treatment line) according to <i>BRAF</i>^<i>V600E</i>mutation in 273 patients with metastatic Colorectal Cancer (B).

<p>Progression Free Survival to salvage treatment with an anti-EGFR monoclonal (stratified for the treatment line) antibody according to <i>BRAF</i>^<i>V600E</i>mutation in 273 patients with metastatic Colorectal Cancer (A) and Median Overall Survival to salvage treatmentwith an anti-EGFR monoclonal antibody (stratified for the treatment line) according to <i>BRAF</i>^<i>V600E</i>mutation in 273 patients with metastatic Colorectal Cancer (B).</p

Patients' outcome according to <i>BRAF</i> mutations status.

<p>Panel A: Time to Tumor Progression (TTP) in the whole patients' population. Panel B: Median Overall Survival (OS) in the whole patients' population Panel C: Time to Tumor Progression (TTP) in patients with <i>KRAS</i> wt primary tumors. Panel D: Median Overall Survival (OS) in patients with <i>KRAS</i> wt primary tumors.</p

Progression Free Survival in 1^st systemic treatment according to BRAF^<i>V600E</i>mutation in 504 patients with metastatic Colorectal Cancer (A) and Median Overall Survival according to BRAF^<i>V600E</i>mutation in 504 patients with metastatic Colorectal Cancer (B).

<p>Progression Free Survival in 1^st systemic treatment according to BRAF^<i>V600E</i>mutation in 504 patients with metastatic Colorectal Cancer (A) and Median Overall Survival according to BRAF^<i>V600E</i>mutation in 504 patients with metastatic Colorectal Cancer (B).</p